Drug Profile


Alternative Names: 1120212; GSK-1120212; GSK-1120212B; JTP-74057; Mekinist; TMT 212

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Japan Tobacco
  • Developer Dana-Farber Cancer Institute; GlaxoSmithKline; Japan Tobacco; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Preregistration Non-small cell lung cancer
  • Phase II Acute myeloid leukaemia; Biliary cancer; Brain metastases; Breast cancer; Cancer; Cervical cancer; Endometrial cancer; Multiple myeloma; Pancreatic cancer; Uveal melanoma
  • Phase I/II Colorectal cancer; Solid tumours
  • Phase I Lymphoma; Mesothelioma
  • No development reported Leukaemia
  • Discontinued Inflammation

Most Recent Events

  • 12 Mar 2017 Novartis withdraws a phase II trial prior to enrolment as supporting company withdrew interest in Gastrointestinal stromal tumors (Metastatic disease, Second-line therapy, Combination therapy) (PO) (NCT02342600)
  • 23 Feb 2017 CHMP recommends approval of trametinib for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in European Union
  • 25 Jan 2017 GlaxoSmithKline withdraws a phase I trial prior to enrollment due to change in strategy for Malignant melanoma (Late-stage disease, Metastatic disease, Combination therapy) in China (NCT02447939)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top